RareResearch.AI
← Back to atlas

G736S

Category 3/4 — Most DruggablePathogenic/Likely pathogenicLumenal · predictedσ-1 candidateEditorial
GlycineSerine at position 736 · C-terminal lumenal domain (653-869) · WFS1 (Wolframin)

A glycine-to-serine substitution at a lumenal turn that brings a free thiol (Cys733) and a histidine (His766) into structural register — backbone freedom is lost where wolframin requires it, and the polar cluster reorganizes.

Interactive 3D Structure

Wild-type reference
Wild-type G736 — hydrogen bond to R732
Fullscreen ↗
DynaMut2 mutant · G736S
Mutant S736 — polar contact contact to H766 lost
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

1 lost1 gained4 preserved
Interaction typeWild-type partnerMutant partnerStatus
Hydrogen bondR732R732Preserved
Polar contactR732R732Preserved
Polar contactH766H766Preserved
Polar contactI767Gained
CarbonylH766Lost
Van der WaalsH766H766Preserved

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
-1.10kcal/mol
Destabilising — moderate
AlphaMissense
0.862
LPath
AlphaFold pLDDT
88
model confidence
Schema
Cat 3/4
Category 3/4 — Most Druggable
ΔΔG confidence: Standard confidence · Lumenal

This variant is in a water-facing region, which is the regime the stability predictor was built and benchmarked for. Ordinary predictor error still applies.

Clinical Evidence

ClinVar classificationPathogenic/Likely pathogenic
Review statuscriteria provided, multiple submitters, no conflicts
Associated conditionsWolfram syndrome 1; Wolfram-like syndrome; Monogenic hearing loss
InheritanceBoth autosomal dominant and autosomal recessive forms documented.
Population frequency (gnomAD v4)Ultra-rare · AF 0.0032%
cDNA changec.2206G>A
ClinVar accessionVCV001328696
Last evaluated2026/01/26 00:00

Observed at very low frequency in gnomAD.

Classified for2★ documented assertion

ClinVar classifies this variant as Pathogenic/Likely pathogenic for Hearing loss, inheritance unstated (inheritance not specified); Wolfram syndrome (classic) (autosomal recessive, OMIM 222300); Wolfram-like syndrome (autosomal dominant, OMIM 614296). These are two clinically distinct disease families: classic Wolfram syndrome requires two affected copies, while the dominant WFS1-related disorders do not. One label covers both, and it does not tell you which applies to a given person.

  • Hearing loss, inheritance unstatedinheritance not specifiedsubmitted as: Monogenic hearing loss
  • Wolfram syndrome (classic)autosomal recessive · OMIM 222300submitted as: Wolfram syndrome 1
  • Wolfram-like syndromeautosomal dominant · OMIM 614296submitted as: Wolfram-like syndrome
  • Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient.
  • Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.

Review status: 2★ multiple submitters, no conflicts. ClinVar "conditions" is the union of all submissions; 0–1★ entries are submitted conditions, not documented phenotypes.

Population frequency
Global (all ancestries)
AF 0.0032% · 52 / 1,612,532 alleles
Homozygotes
0
Highest-frequency population
East Asian · AF 0.0089%

Highest in East Asian: AF 0.0089% (4 of 44,866 alleles), 2.8x the global figure. The global AF describes the general population, not the at-risk group.

No homozygotes reported in gnomAD v4. For a recessive allele this is expected and is not, on its own, evidence either way.

Ancestry groupAllele freq.AC / ANHom.Carrier est.
East Asian0.0089%4 / 44,8660~1 in 5610
European (non-Finnish)0.0037%44 / 1,179,9160~1 in 13410
Remaining individuals0.0032%2 / 62,4520~1 in 15610
Admixed American · under-sampled0.0017%1 / 59,9740
South Asian · under-sampled0.0011%1 / 91,0680

Source: gnomAD r4, retrieved 2026-08-21. Values are allele frequencies. The carrier estimate is derived from the allele frequency (Hardy-Weinberg, ~2·AF) and is an approximation, not a published figure — where a published carrier frequency exists it outranks this column and is cited on the card.

Structural Context

G736 is wedged between Glu737 (2.41 Angstrom) and Tyr735 (2.47 Angstrom), with a through-space contact cluster reading Arg732 (3.07 Angstrom), His766 (3.29 Angstrom), Ile767 (4.09 Angstrom), Cys733 (4.88 Angstrom), and Leu734 (5.00 Angstrom). The local geometry is structurally complex: a tyrosine-glycine-glutamate sequence sandwiched between an arginine three residues upstream, a histidine six residues downstream by sequence but within 3.3 Angstrom by space, and a free cysteine within 5 Angstrom.

The wild-type glycine at 736 is doing exactly what glycines do best — providing the backbone flexibility that brings Arg732 (3.07 Angstrom), the Tyr735 phenol, and His766 (3.29 Angstrom) into close polar register. The Tyr735 hydroxyl, the Arg732 guanidinium, the Glu737 carboxylate, and the His766 imidazole are all polar-functional groups that the local geometry stages into a hydrogen-bond / electrostatic network. Glycine's job here is to allow the backbone turn that makes this network possible.

Replacing G736 with serine removes the disallowed-region phi/psi freedom and forces the chain into standard geometry. The Tyr735-Arg732-His766 register opens up; the Glu737 contact shifts; the local polar network — which is almost certainly part of the lumenal-domain functional surface — is degraded. DynaMut2's DeltaDeltaG of -1.1 kcal/mol captures the moderate destabilization; AlphaMissense at 0.862 confirms the position is evolutionarily constrained.

The Cys733 at 4.88 Angstrom is a secondary concern. In the wild-type configuration, the geometry holds Cys733 in a defined position relative to the polar cluster. The G736S-induced rearrangement may expose Cys733's thiol to a different local environment, potentially raising disulfide-formation risk in the oxidizing ER lumen. This is inference, not observation, but the structural signature supports it.

ClinVar links G736S to Wolfram syndrome 1, Wolfram-like syndrome, and monogenic hearing loss — phenotypic breadth consistent with partial loss of lumenal-domain function.

Amino-acid chemistry
Glycine (no side chain, uniquely permissive backbone freedom — the only amino acid that fits Ramachandran-disallowed phi/psi regions) to Serine (small polar hydroxyl, restricted to standard backbone geometry) at position 736.
Position in the protein
Position 736 sits in wolframin's C-terminal lumenal domain (residues 653-869) — the ATF6-interacting, Na+/K+ ATPase beta1-contacting, calcium-handling module. pLDDT 88.12 places G736 in an ordered, well-modeled environment.

Druggability Assessment

Final classification: Category 3 — Most Druggable. pLDDT 88.12, DeltaDeltaG magnitude 1.1 kcal/mol, AlphaMissense 0.862, lumenal placement — the convergent profile sits inside the pharmacological-chaperone bucket. The lesion is a single backbone-freedom loss with downstream effects on a polar functional cluster (Arg732, Tyr735, His766, Glu737). The drug design target is the multi-residue polar cluster, not G736 itself. A small molecule that engages the Arg732-Tyr735-His766 arrangement and restores the wild-type geometric register should compensate for the lost glycine flexibility. The Cys733 disulfide-formation risk should be modeled explicitly: any candidate compound should be tested for whether it stabilizes Cys733 in its reduced state.

Why this matters

G736S is another representative of the lumenal glycine-loss cluster (alongside G702S, G695D, and others). The Atlas should treat these as a mechanistically unified set — same loss type (backbone freedom), same domain (lumenal), and likely overlapping chaperone-screening hits. If a single small molecule rescues two or three lumenal glycine-loss variants, the screening hit ratio for downstream development jumps substantially. For the wolframin program, mapping the constellation of glycines in the lumenal domain is high-leverage atlas work. Each is potentially a Cat 3 variant; together they constitute a chemically tractable set with shared design logic.
Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the G736S PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download G736S PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.

UniProt Domain Annotation

Chain1890 · Wolframin
Topological domain653869 · Lumenal
Natural variant736736 · in WFS1; dbSNP:rs71532864